Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brad C Klein

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Headache|March 16, 2022
Asking the right questions: The value of headache specialty careBrad C Klein
Headache|July 19, 2019
Getting to the Heart of the Matter: Migraine, Triptans, DHE, Ditans, CGRP Antibodies, First/Second-Generation Gepants, and Cardiovascular RiskPaul G Mathew, Brad C Klein
Neurology|April 3, 2020
COVID-19 is catalyzing the adoption of teleneurologyBrad C Klein, Neil A Busis
Cephalalgia : an International Journal of Headache|March 6, 2018
Association of neurologist care with headache expenditures: A population-based, longitudinal analysisJohn P Ney, Jason J Sico, Brad C Klein, et al.
Headache|April 11, 2016
A retrospective analysis of triptan and dhe use for basilar and hemiplegic migrainePaul G Mathew, Regina Krel, Bhuvin Buddhdev, et al.
Headache|April 1, 2020
Migraine Care in the Era of COVID-19: Clinical Pearls and Plea to InsurersChristina L Szperka, Jessica Ailani, Rebecca Barmherzig, et al.
Neurology|July 14, 2022
Futures Planning at the AAN: Approach and Initial OutcomeCarlayne E Jackson, Lyell K Jones, Brad C Klein, et al.
Cephalalgia : an International Journal of Headache|January 9, 2023
Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trialBrad C Klein, Rosa Miceli, Lawrence Severt, et al.
Neurology|July 26, 2023
Antiamyloid Monoclonal Antibody Therapy for Alzheimer Disease: Emerging Issues in NeurologyVijay K Ramanan, Melissa J Armstrong, Parichita Choudhury, et al.
Neurology. Clinical Practice|October 14, 2024
Characterizing Prodrome (Premonitory Phase) in Migraine: Results From the PRODROME Trial Screening PeriodTodd J Schwedt, Richard B Lipton, Peter J Goadsby, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Headache|March 16, 2022
Asking the right questions: The value of headache specialty careBrad C Klein
Headache|July 19, 2019
Getting to the Heart of the Matter: Migraine, Triptans, DHE, Ditans, CGRP Antibodies, First/Second-Generation Gepants, and Cardiovascular RiskPaul G Mathew, Brad C Klein
Neurology|April 3, 2020
COVID-19 is catalyzing the adoption of teleneurologyBrad C Klein, Neil A Busis
Cephalalgia : an International Journal of Headache|March 6, 2018
Association of neurologist care with headache expenditures: A population-based, longitudinal analysisJohn P Ney, Jason J Sico, Brad C Klein, et al.
Headache|April 11, 2016
A retrospective analysis of triptan and dhe use for basilar and hemiplegic migrainePaul G Mathew, Regina Krel, Bhuvin Buddhdev, et al.
Headache|April 1, 2020
Migraine Care in the Era of COVID-19: Clinical Pearls and Plea to InsurersChristina L Szperka, Jessica Ailani, Rebecca Barmherzig, et al.
Neurology|July 14, 2022
Futures Planning at the AAN: Approach and Initial OutcomeCarlayne E Jackson, Lyell K Jones, Brad C Klein, et al.
Cephalalgia : an International Journal of Headache|January 9, 2023
Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trialBrad C Klein, Rosa Miceli, Lawrence Severt, et al.
Neurology|July 26, 2023
Antiamyloid Monoclonal Antibody Therapy for Alzheimer Disease: Emerging Issues in NeurologyVijay K Ramanan, Melissa J Armstrong, Parichita Choudhury, et al.
Neurology. Clinical Practice|October 14, 2024
Characterizing Prodrome (Premonitory Phase) in Migraine: Results From the PRODROME Trial Screening PeriodTodd J Schwedt, Richard B Lipton, Peter J Goadsby, et al.
Pageof 2